Duhok acromegaly; a prospective cohort study
DOI:
https://doi.org/10.56056/amj.2017.28Keywords:
Acromegaly, DuhokAbstract
Background and objectives:Acromegaly is a rare hormonal disorder; the prevalence is around 60 cases/ million population, incidence is3.3new cases/million/year. Mortality rate 2 to 4 times that of general population. It is usually the result of a somatotrope adenoma in more than 95% of cases.The aim is to study our patient`s characteristics, to identify the best management for acromegaly, which can induce clinical, and biochemical remission, also this paper aimed to increase acromegaly awareness regarding the importance of early diagnosis of this disease.
Methods:This is prospectivecohort study involving 15patients; the duration of study is 2 years (June 2015-June 2017). All patients diagnosed by high level of insulin-like growth factor 1 followed by growth hormone suppression test and MRI of pituitary gland. Those patients underwent transsphenoidal resection, diagnosis confirmed by histopathology too.
Results:The median age of patients at presentation was 47.3 (SD 9.9), with majority between 40-50 years. Females constitute 8 of the patients, while number of males was 7. The most common chief complaint was headache accounting for 40% of cases. All patients at presentation were suffering from macroadenoma.The combination of surgical and medical treatment was more successful in reducing GH and IGF1 levels in comparison to medical treatment alone (p value of <0.001 and 0.037 respectively).
Conclusions:The combination of surgical and medical treatment was superior to medical treatment alone in reducing GH , IGF1 level and inducing tumor remission.The two dilemmas we are facing here in Duhok are: First; delayed diagnosis as reflected by the fact all of our patients were macroadenoma at presentation, that is why we need to increase awareness about this disease and the importance of early diagnosis and early referral before onset of complications which directly associated with increase mortality. Secondly; low compliance for medical treatment, to improve this we need to provide free measurements of both GH and IGF1 levels for all patients receiving somatostatin analogue treatment
Downloads
References
Nabarro JD. Acromegaly. ClinEndocrinol (Oxf). 1987;26:481-512
DalyAF, Rixhon M, Adam C, DempegiotiA, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J ClinEndocrinolMetab. 2006; 91:4769- 4775.
Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG. Acromegaly: clinical and biochemical features in 500 patients. Medicine (Baltimore). 1994; 73:233-240.
Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am. 1992; 21:597-614.
Drange MR, Fram NR, Herman-Bonert V, Melmed S. Pituitary tumor registry: a novel clinical resource. J ClinEndocrinolMetab. 2000; 85:168-174.
Swearingen B, Barker FG II, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J ClinEndocrinolMetab. 1998; 83:3419-3426.
Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. ClinEndocrinol (Oxf). 1980; 12:71-79.
Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. ClinEndocrinol (Oxf). 1994; 41:95- 102.
Mechanick JI, Bergman DA, Braithwaite SS, Palumbo PJ.American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines [published correction appears in EndocrPract. 2008;14:802-803]. EndocrPract. 2004; 10:353-361.
Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity, and mortality in acromegaly based on the Spanish Acromegaly Registry (RegistroEspanol de Acromegalia, REA). Eur J Endocrinol. 2004; 151:439-446.
Rivoal O, Brézin AP, Feldman-Billard S, Luton JP. Goldmann perimetry in acromegaly: a survey of 307 cases from 1951 through 1996. Ophthalmology. 2000; 107:991-997.
Melmed S. Medical progress: acromegaly [published correction appears in N Engl J Med. 2007; 356:879]. N Engl J Med. 2006; 355:2558-2573.
Brabant G, von zurMühlen A, Wüster C, et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res. 2003; 60:53-60. [EL 1]
Melmed S. Confusion in clinical laboratory GH and IGF-I reports. Pituitary. 1999; 2:171-172.
Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J ClinEndocrinolMetab. 1998; 83:3808-3816.
Giustina A, Chanson P, Bronstein MD, et al (Acromegaly Consensus Group). A consensus on criteria for cure of acromegaly. J ClinEndocrinolMetab. 2010; 95:31413148.
Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG. Acromegaly: clinical and biochemical features in 500 patients. Medicine (Baltimore). 1994; 73:233-240.
Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am. 1992; 21:597-614.
Nabarro JD. Acromegaly. ClinEndocrinol (Oxf). 1987; 26:481-512.
Swearingen B, Barker FG II, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J ClinEndocrinolMetab. 1998; 83:3419-3426.
Jadresic A, Banks LM, Child DF, et al. The acromegaly syndrome: relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours. Q J Med. 1982; 51:189-204.
Colao A, Pivonello R, Scarpa R, Vallone G, Ruosi C, Lombardi G. The acromegalic arthropathy. J Endocrinol Invest. 2005; 28(8 suppl):24-31.
Lacks S, Jacobs RP. Acromegalic arthropathy: a reversible rheumatic disease. J Rheumatol. 1986; 13:634-636.
Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J ClinEndocrinolMetab. 2005; 90:27312739.
Biering H, Knappe G, Gerl H, Lochs H. Prevalence of diabetes in acromegaly and Cushing syndrome [in German]. Acta Med Austriaca. 2000; 27:27-31.
Kasayama S, Otsuki M, Takagi M, et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. ClinEndocrinol (Oxf). 2000; 52:549-555.
Lombardi G, Galdiero M, Auriemma RS, Pivonello R, Colao A. Acromegaly and the cardiovascular system. Neuroendocrinology. 2006; 83:211-217.
Kraatz C, Benker G, Weber F, Lüdecke D, Hirche H, Reinwein D. Acromegaly and hypertension: prevalence and relationship to the renin-angiotensin-aldosterone system. KlinWochenschr. 1990; 68:583-587.
Otsuki M, Kasayama S, Yamamoto H, et al. Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. ClinEndocrinol (Oxf). 2001; 54:791-796.
Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004; 25:102-152.
Vitale G, Pivonello R, Galderisi M, et al. Cardiovascular complications in acromegaly: methods of assessment. Pituitary. 2001; 4:251-257.
Jane JA Jr, Thapar K, Laws ER Jr. Acromegaly: historical perspectives and current therapy. J Neurooncol. 2001; 54:129-137.
Atkinson JL, Nippoldt TB. Pituitary neurologic surgery: a unique subspecialty in evolution. EndocrPract. 2002; 8:356-361.
Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA. The outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. ClinEndocrinol (Oxf). 1999; 50:561-567.
Kreutzer J, Vance ML, Lopes MB, Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J ClinEndocrinolMetab. 2001; 86:4072-4077.
Minniti G, Jaffrain-Rea ML, Esposito V, Santoro A, Tamburrano G, Cantore G. Evolving criteria for postoperative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. EndocrRelat Cancer. 2003; 10:611-619.
Davis DH, Laws ER Jr, Ilstrup DM, et al. Results of surgical treatment for growth hormone-secreting pituitary adenomas. J Neurosurg. 1993; 79:70-75.
Petrossians P, Borges-Martins L, Espinoza C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol. 2005; 152:61-66.
Shimon I, Cohen ZR, Ram Z, Hadani M. Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery. 2001; 48:12391245.
Katznelson L. Drug insight: primary medical therapy of acromegaly. Nat ClinPractEndocrinolMetab. 2006; 2:109- 117.
Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J ClinEndocrinolMetab. 2006; 91:1397-1403.
Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J ClinEndocrinolMetab 2006; 91(6): 2112–2218
Yetkin DO, Boysan SN, Tiryakioglu O, Yalin AS, Kadioglu P. Forty-month follow-up of persistent and difficultly controlled acromegalic patients treated with depot long-acting somatostatin analog octreotide. Endocr J. 2007; 54:459-464.
Colao A, Ferone D, Lastoria S, et al. Prediction of the efficacy of octreotide therapy in patients with acromegaly. J ClinEndocrinolMetab. 1996;81: 2356-2362.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Bayar Ahmed Qasim
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in AMJ (The Scientific Journal of Kurdistan Higher Council of Medical Specialties )is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0)
